June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.Unlock Stocks

More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying

Published 08/07/2022, 13:25
Updated 08/07/2022, 14:10
© Reuters.  More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying
CAPR
-
MCRB
-

U.S. stock futures traded lower this morning on Friday ahead of jobs report for june. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3

Seres Therapeutics

  • The Trade: Seres Therapeutics, Inc. (NASDAQ: MCRB) 10% owner Noubar Afeyan acquired a total of 8,738,243 shares at an average price of $3.15. To acquire these shares, it cost around $27.53 million.
  • What’s Happening: Seres Therapeutics recently announced a $100 million registered direct offering of common stock.
  • What Seres Therapeutics Does: Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States.
Capricor Therapeutics
  • The Trade: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Chief Business Officer Xavier Avat acquired a total of 2,500 shares at an average price of $3.73. The insider spent around $9.32 thousand to buy those shares.
  • What’s Happening: Capricor Therapeutics recently announced one-year results from its HOPE-2 open label extension study in non-ambulant patients with later-stage duchenne muscular dystrophy.
  • What Capricor Therapeutics Does: Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions.
U.S. Jobs Growth Might Slow To This Level In June, Here's The Major Macro Issues For Friday

Don’t forget to check out our premarket coverage here .

Rafael Holdings

  • The Trade: Rafael Holdings, Inc. (NYSE: RFL) Executive Chairman Howard Jonas acquired a total of 3,225,806 shares at an average price of $1.86. To acquire these shares, it cost around $6 million.
  • What’s Happening: Rafael Holdings, last month, posted a Q3 loss of $0.28 per share.
  • What Rafael Holdings Does: Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.
PHX Minerals
  • The Trade: PHX Minerals Inc. (NYSE: PHX) 10% owner Jonathan Brolin acquired a total of 11,054 shares at an average price of $2.66. The insider spent $29.39 thousand to buy those shares.
  • What’s Happening: PHX Minerals, during May, posted a Q2 loss of $0.12 per share.
  • What PHX Minerals Does: PHX Minerals, previously Panhandle Oil & Gas, is an oil and natural gas mineral company that has employed a strategy to shift the core of its business away from drilling and toward perpetual mineral and natural gas ownership.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.